← All trials
NCT02015923
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2013
- Primary completion
- Nov 1, 2017
- Completion date
- Nov 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 336
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of BarcelonaLead sponsor
- Corporacion Parc TauliOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
- University of SevilleOverall official - principal investigator
- Complejo Hospitalario La Mancha CentroOverall official - principal investigator
- University of OrenseOverall official - principal investigator
- University of VigoOverall official - principal investigator
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOverall official - principal investigator
- OsakidetzaOverall official - principal investigator
- Universidad Carlos III MadridCollaborator
- Clinica Universidad de NavarraOverall official - principal investigator
- University of BarcelonaStudy chair
- University of BarcelonaReponsible party - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.